LSL Pharma loses $2.8-million in Q1 2026

• LSL Pharma Group reported Q1 2026 consolidated revenues of $12.3 million, an 86% increase year-over-year compared to Q1 2025 ($6.6 million).
• Despite record revenue growth, the company posted a net loss of $2.8 million for the quarter, contrasting with a $200,000 profit in Q1 2025.
• The loss is attributed primarily to a three-month production pause at Steri-Med Pharma (January to March 2026) and integration costs from recent acquisitions (Juno OTC and Du-Var).
• Production at the Steri-Med plant resumed in April 2026 following Health Canada's acceptance of a remediation plan.
• The company secured US FDA certification for Steri-Med to manufacture ophthalmic ointment, opening access to the U.S. market.
• Strategic acquisitions include Juno OTC (acquired Jan 1, 2026) and Du-Var (acquired Nov 17, 2025), contributing to revenue growth but increasing SG&A expenses from $1.7 million to $2.6 million.
• Financing updates include an increased revolving credit facility ($7.5M to $11M) and a $12 million convertible debt offering closed in December 2025.

• Revenue Growth: The 86% revenue increase is significant and exceeds the projected annualized run rate implied by previous acquisition announcements (Juno OTC expected ~$25M for full year 2026; Q1 alone suggests higher trajectory). This validates the M&A strategy.
• Profitability Concerns: A $2.8 million quarterly loss is material and alarming, as it equals the entire net loss reported for FY 2025 ($2.8M) in just one quarter. This indicates a high cash burn rate that threatens liquidity despite the credit facility increase.
• Operational Resolution: The production pause was known (Jan-Mar), so its impact on Q1 results is expected rather than unexpected news, though the resumption in April is positive for future quarters.
• Debt and Dilution: The $12 million convertible debentures carry a conversion price of $0.45 per share, which is above the current trading price ($0.35). This creates significant dilution risk if shares are converted or if the stock does not recover to trigger cash repayment.
• Net Assessment: While revenue growth is positive, the acceleration in losses and high burn rate prevent a "Material - Positive" rating from a risk-averse perspective. The news confirms known risks (integration costs) rather than introducing new upside catalysts beyond what was priced in during acquisition announcements.

• Company: LSL Pharma Group Inc., a Canadian pharmaceutical company focused on contract manufacturing (CMO), eye-care products, and private label OTC drugs.
• Flagship Project: Steri-Med Pharma plant, which manufactures sterile ophthalmic solutions and ointments. Recently secured US FDA certification for ophthalmic ointment production.
• Segments: CMO ($6.2M revenue), Eye-care ($1.5M revenue), Private Label ($4.6M revenue).
• Strategic Focus: Expansion through acquisitions (Juno OTC, Du-Var) to diversify product portfolio and increase manufacturing capacity.
• Regulatory Status: Health Canada approved six sterile ophthalmic solutions; US FDA certified for ointment manufacturing.